Podcasts about antibodies

In our natural bodies, there are many things inside that keep us alive, although we’ve never seen them. Antibodies, clotting agents, intestinal flora, white blood cells. Now, spiritually speaking, there are invisible forces at work that want to help us and save us, although other forces want to destroy us. Today on A NEW BEGINNING, Pastor Greg Laurie points out the work of God’s Spirit acquaints us with our sin, and acquaints us with our Savior. It’s important we know how to respond. Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

In our natural bodies, there are many things inside that keep us alive, although we’ve never seen them. Antibodies, clotting agents, intestinal flora, white blood cells. Now, spiritually speaking, there are invisible forces at work that want to help us and save us, although other forces want to destroy us. Today on A NEW BEGINNING, Pastor Greg Laurie points out the work of God’s Spirit acquaints us with our sin, and acquaints us with our Savior. It’s important we know how to respond. Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.

Is the “poop pill” a possible treatment for small intestinal bacterial overgrowth (SIBO)? Pro-mask, pro-lockdown, pro-vax words come back to haunt their authors as Covid response critics appointed to key HHS positions; MAHA influencer Dr. Casey Means replaces original Surgeon General nominee; Rating Trump's new vaccine czar, oncologist Vinay Prasad; Is Laetrile effective for cancer? If you're eating a diet rich in fruits and vegetables, do you still need probiotics? Researchers tap an unusual source for antivenom against deadly snakebites—a snake handler who's survived multiple poisonings.

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Download the transcript here

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Listen to the podcast here

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in headcount at IgM Biosciences. The FDA has faced delays, including missing review dates for GSK's Nucala. President Trump is expected to unveil a drug pricing plan on Monday that has been criticized by big pharma and patient groups. Lotte Biologics offers end-to-end services for ADC manufacturing in Syracuse, NY. Rallybio, Insitro, Shape, and Vor have all downsized their workforces.

This week, we round out our discussion we started in our prior episode on APLS, this time focusing on management. Stick around until the end to hear Dan and Vivek battle it out about the optimal time to recommend APLS testing for your patients!If you have not done so already, we highly recommend you check out episode 134 (diagnosis of APLS) prior to jumping into this one!Episode contents:- What is the best choice of anticoagulant? - Is a higher INR better for warfarin? - Are DOACs acceptable options? - What is the optimal time to send APLS testing? **** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this episode of the Ducks Unlimited Podcast, we're joined by Dr. RuthAnn Lobos of Purina. We dive deep into puppy health, discussing essential vaccines, building immunity, the science behind proper nutrition, and why it all matters for your duck dog. Plus, Dr. Lobos shares valuable socialization tips to help your puppy grow into a confident hunting companion.Listen now: www.ducks.org/DUPodcastSend feedback: DUPodcast@ducks.org

If you've ever Googled your way into confusion, felt unsure about treatments, or just wished someone would break it all down in plain language—this QA episode is for you.Dr. Eric answers listener questions with clarity and care, breaking down complex topics like postpartum hyperthyroidism, iodine contrast risks in CT scans, and the role of inulin in gut health. He also shares insights on natural remedies like bugleweed and castor oil packs, managing hormone therapy, and addressing elevated homocysteine levels. Plus why gut health, genetics, and lifestyle all play a part. It's a clear, helpful look at the thyroid questions so many are asking.Tune in now for insights that can help you feel more in control of your thyroid journey.Episode Timeline: 0:00 – Episode introduction 0:16– Overview of thyroid and autoimmune conditions0:30 - Do CT Scans with Contrast Harm Your Thyroid?1:41 - Postpartum Hyper to Hypothyroid Flop4:10 - Is Inulin Safe for Hashimoto's?5:42 - Bugleweed, Antibodies and the Hyper Cycle8:16 - Tackling High Homocysteine Levels10:12 - Can Genes Flip You from Graves to Hypo?11:48 - Is Quercetin Safe with Desiccated Thyroid?13:28 - Natural Ways to Handle Hyperthyroidism14:39 - Thoughts on Rife Frequencies and Healing20:31 - Short Break21:21 - Always Low T3 Despite Meds22:34 - Does an Uptake Scan Change Anything?23:06 - High Antibodies but Labs Look Good23:41 - Treating Hyperthyroid While Breastfeeding25:42 - Does Thyroxine Fix Hashimoto's or Just Mask It?26:39 - Subclinical Hyper or Something Else28:57- Can an Ultrasound Trigger Seizures?29:51 - HRT and Possible Thyroid Flare31:41 - What's Optimal Free T3 and Reverse T3?32:57 - Can You Fully Reverse Subclinical Hyper?33:38 - Lab Variability and Tracking Bugleweed Effects36:51 - Healing Hyperthyroidism Without Meds37:41 - Hoping to Get Off Levothyroxine Naturally39:47 - Can You Take Bugleweed While on Meds?40:37 - Is Hydrogen Water Safe with Thyroid Meds?41:24 - Can You Take T3 on Its Own?43:08 - Wrapping Up the Q&A43:31 - Where to Ask More Questions43:49 - Submit Your Questions for Future Episodes44:00 - Podcast OutroMentioned In This Episode: Dr. Eric' BooksNatural Treatment Solutions for Hyperthyroidism and Graves' Disease Amazon.com: The Hyperthyroid Healing Diet: Reverse Hyperthyroidism and Graves' Disease and Save Your Thyroid Through Diet and Lifestyle Changes Hashimoto's Triggers: Eliminate Your Thyroid Symptoms By Finding And Removing Your Specific Autoimmune TriggersDr. Eric's Podcast: How To Lower Thyroid AntibodiesHow To Lower Thyroid Antibodies Part 1Saving Your Thyroid Through Rad Do You Want Help Saving Your Thyroid? Access hundreds of free articles at www.NaturalEndocrineSolutions.com Visit Dr. Eric's YouTube channel at www.youtube.com/c/NaturalThyroidDoctor/ To work with Dr. Eric, visit https://savemythyroid.com/work-with-dr-eric/

The highly intelligent Carol Petersen is back to discuss Thyroid health but first...We apologize for some of the breaks in this conversation, we are both having issues with our WIFI but hopefully you still find this helpful. The podcast version has most of the breaks taken out, so will be clearer to listen to. Thank you for understanding. :) But this really is a fantastic very considered conversation around Thyroid health and hypothyroidism with Carol.

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines. With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before.Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTsAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient's perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx. “[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I'm not just a number, I'm a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett   Nancy Mallett Patient Advocate   Resources:  FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD  Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP  ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8  Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962  Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ    Funder Statement  This program is supported by AbbVie.   

This week, we continue our series focusing on venous thromboembolism. In this episode, we begin our discussion of antiphospholipid syndrome.Episode contents:- What is "antiphospholipid antibody syndrome"?- How do we make this diagnosis?- What is the optimal time to test for these antibodies? **** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Listen to the podcast here

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Download the transcript here

What was the world's top selling drug in 2023? Maybe the magic weight losing drug semaglutide, better known as Ozempic? Or the COVID vaccine perchance? Nope. 2023's top selling drug was an antibody, Keytruda, with about $25 billion in sales. $27 billion projected for 2024. In fact, five of the top ten best selling drugs in 2023 were antibodies. Antibody therapies revolutionized medicine. We have long known they can. The problem has always been how to make them the right way and at industrial scale. Today it is done with the help of a hamster. Or rather its cells. In this video, the incredible story of the hamster that revolutionized medicine. This is one of my favorite videos of the year.

What was the world's top selling drug in 2023? Maybe the magic weight losing drug semaglutide, better known as Ozempic? Or the COVID vaccine perchance? Nope. 2023's top selling drug was an antibody, Keytruda, with about $25 billion in sales. $27 billion projected for 2024. In fact, five of the top ten best selling drugs in 2023 were antibodies. Antibody therapies revolutionized medicine. We have long known they can. The problem has always been how to make them the right way and at industrial scale. Today it is done with the help of a hamster. Or rather its cells. In this video, the incredible story of the hamster that revolutionized medicine. This is one of my favorite videos of the year.

Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and diffuse large B-cell lymphoma (52:53) NCPD information and select publications

Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.

Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

Katie's ostrich farm in British Columbia fights federal agencies seeking to cull 400 healthy ostriches in an effort to shut down groundbreaking research into natural antibodies and sustainable agriculture.Key topics discussed:- Ostrich antibodies for human health and disease prevention- Partnership with Japan's Dr. Sakamoto and global patents- COVID-era suppression of immune-based research- Government culling orders and legal pushback- Threats to natural immunity, food sovereignty, and farm independenceSave Our Ostriches:WebsiteDonateInstagramX RumbleUpdates + Additional Info

Send us a textIf you like learning about the mysteries of the immune system - you're going to like this episode! Dr Yas makes learning about the immune system fun - even going so far as to create poke-immune cards on instagram. If you are a pokemon fan & science lover - you'll love it. Check out an example below.Dr Yasmin Mohseni, PhD is an immunologist with 6+ years of experience in the cell and gene therapy biotech space, specialising in immunotherapy for cancer and immunoregulation. Dr Mohseni earned her PhD in Immunotherapy from King's College London, where she focused on using engineered regulatory T cells (Tregs) to promote immune tolerance in solid organ transplantation with applications to autoimmunity. She began her industry journey at Quell Therapeutics, advancing Treg-based therapies, and now works at A2 Biotherapeutics in the cancer immunotherapy space, developing therapies for solid tumours. She currently serves as the scientific lead within Quality, bridging analytical strategy, process and product knowledge improvements within CMC.Dr. Yasmin Mohseni is an immunologist with an interest in immunology and cancer biotech. She discusses the emotional complexities of being an IBD patient while also being a scientist, the intricacies of the immune system, and her current role in developing immunotherapies for cancer treatment. The conversation highlights the importance of understanding the immune system's balance and the potential of immunotherapy in revolutionizing the future healthcare. In this conversation, Dr. Yasmin Mohseni delves into the complexities of the immune system, particularly in relation to Inflammatory Bowel Disease (IBD), immune memory and the effects of stress. The discussion highlights the mechanisms of immune responses, the role of cytokines, and how various factors, including hormones and stress, can influence immune health and disease progression.Takeaways-Dr. Yasmin Mohseni shares her experience of becoming an immunologist.Immunology is about communication between cells.T cells play a crucial role in fighting cancer.Immunotherapy is changing the landscape of cancer treatment.The immune system not only protects the body from invaders but also aids in healing and repair.Inflammation is a natural response to infection.Understanding the immune system can empower patients. IBD involves complex immune responses and genetic predispositions.Cytokines serve as crucial communicators in the immune system.Antibody presence does not always indicate immune memory.Chronic stress can lead to dysregulated immune responses.Pregnancy can alter immune responses, affecting autoimmune diseases..Understanding immune memory is essential for vaccine responses.The relationship between hormones and immunity is nuanced and complex.Follow us on instagram @crohns_and_colitis_dietitiansFollow us on youtube @thecrohnscolitisdietitiansWe love helping provide quality content on IBD nutrition and making it more accessible to all through our podcast, instagram and youtube channel. Creating the resources we provide comes at a significant cost to us. We dream of a day where we can provide even more free education, guidance and support to those with IBD like us. We need your support to do this. You can help us by liking episodes, sharing them on your social media, subscribing to you tube and telling others about us (your doctors, friends, family, forums/reddit etc). Can you do this for us? In return, I promise to continually level up what we do here.

Send us a textWhat if we could revolutionize biotechnology by slashing antibody production costs by 70%? In a world where traditional mammalian cell cultures struggle with scalability and cost-effectiveness, an unexpected hero emerges from the depths of our oceans - microalgae.The use of microalgae in biotechnology is not just a novelty but a necessity, given the current demands for more efficient and cost-effective production methods. Muriel Bardor, co-founder, CEO and CSO of Alga Biologics, highlights a particularly startling statistic: microalgae can reduce the cost of antibody production by an impressive 70%. This innovation could revolutionize the biotechnology industry by making life-saving therapies more accessible.Here are 3 key takeaways from this podcast episode:Quality and Safety Assurance: By collaborating with virology experts and using advanced techniques like mass spectrometry, they ensure that their processes are virus-free and free from host-cell protein contamination. The company is paving the way for future developments despite the challenges of not having standard ELISA kits commercially available.Regulation and Industry Perception: Launching such transformative technology inevitably entwines with regulatory landscapes. Muriel and her company have begun discussions with the French regulatory agency, drawing optimism from the fact that similar plant-based products, such as glucocerebrosidase, have already paved the way in the market. This indicates a growing acceptance within regulatory bodies of alternative bioprocessing platforms, inspiring hope for microalgae's future in antibody production.Future Vision: Muriel hopes to break conservative barriers within pharmaceutical companies and promote the adoption of microalgae production. This offers not only cost-effective solutions but also holds potential for new treatment options, like for neuroblastoma.Check out the episode to hear Muriel's advice for aspiring scientists and the general public alike regarding the future of research and the well-being of our planet.Connect with Muriel Bardor:LinkedIn: www.linkedin.com/in/muriel-bardor-47953024Email: muriel.bardor@univ-rouen.frAlga Biologics: www.algabiologics.comNext step:Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.Featured Articles:Aging platelets shift their hemostatic properties to inflammatory functionsOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyDissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases will benefit from therapeutic antibody development?” In the first article, Katie Abouzahr is the Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at the Janssen Pharmaceutical Companies of Johnson & Johnson. She speaks with Megan Thomas about the future for Janssen's investigational medicine nipocalimab and antibody therapeutics at large. In the second article, DDW's Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies.

Season 5: Episode 207In this North American Ag Spotlight podcast episode, host Chrissy Wozniak interviews Katie Pasitney from Universal Ostrich, a family-owned ostrich farm in British Columbia, Canada. The farm, which has been raising ostriches for 35 years, is facing a crisis due to a government order to cull over 400 ostriches amid an avian flu outbreak, despite most birds showing resistance and antibodies to the virus.Katie explains that the farm has shifted focus in recent years to groundbreaking antibody research in collaboration with Kyoto Prefectural University in Japan. They inoculate ostriches with antigens to produce robust antibodies in their egg yolks, which could be used to create nutraceuticals like lozenges and nasal sprays to boost human immunity against diseases, including COVID-19 variants. This research has shown promising results, with one ostrich egg containing antibodies equivalent to 100 chicken eggs or the blood of 800 rabbits, offering a humane and efficient alternative.The crisis began in December 2024 when the farm noticed symptoms similar to a 2020 pseudomonas bacteria outbreak, initially linked to migratory mallard ducks. However, the Canadian Food Inspection Agency (CFIA), acting on an anonymous tip, tested two deceased ostriches and confirmed H5N1 avian influenza using PCR tests, rejecting the farm's request to test healthy birds or conduct a broader study. Despite the farm's isolation and the ostriches' apparent herd immunity—evidenced by 76 days without symptomatic deaths post-quarantine—the CFIA ordered the entire flock's destruction, citing trading partner policies influenced by the World Health Organization and the UN.Katie highlights the farm's struggle against what she calls a “stamping out” policy that prioritizes mass culling over preserving natural immunity, potentially benefiting Big Pharma by eliminating alternatives to vaccines. The CFIA has threatened a $250,000 fine or jail time if the farm tests its own animals, and even probed for intellectual property during a 5.5-hour meeting, despite having already signed a kill order on December 30, 2024. The family faces a deadline to kill and bury the ostriches themselves or lose compensation if a third-party contractor intervenes.With a judicial review scheduled for mid-April, the farm is fighting legally to save their ostriches and research, having raised over $60,000 for legal fees but facing $100,000 more in outstanding costs. Katie pleads for public support, emphasizing the global implications for agriculture and natural immunity, and directs listeners to saveourostiches.com for updates and donations.Chrissy underscores the story's urgency, calling for action against government overreach and the preservation of this potentially revolutionary science, urging listeners to share the episode and support the cause. Learn more about this cause at https://bcrising.ca/save-our-ostriches/ and give to the cause at https://www.givesendgo.com/save-our-ostriches or https://www.gofundme.com/f/help-ostrich-farmers-fight-to-save-herd-from-avian-flu?attribution_id=sl%3A80e09934-7413-429b-acfb-2f7015cc19d3&lang=en_CA#ostrich #farming #agricultureDon't just thank a farmer, pray for one toSend us a textAgritechnica in Hannover, Germany is held every other year, this year long-time tech writer & ag journalist Willie Vogt has put together for ag enthusiasts! The Agritechnica tour includes three days at the huge equipment and farm technology event. Learn more - https://agtoursusa.com/agritechnica.htmlSubscribe to North American Ag at https://northamericanag.com

Send us a textThe world of biologics manufacturing is about to be transformed by a breakthrough that slashes antibody production costs by 70%. This revolutionary approach leverages the untapped potential of microalgae to deliver a sustainable, cost-effective solution that could make life-saving therapeutics more accessible than ever before. Enter microalgae, the star of this groundbreaking development.In this episode of the Smart Biotech Scientist, Muriel Bardor, the co-founder, CEO and CSO of Alga Biologics, shared insights into how her team's pioneering work with microalgae could redefine the landscape of immunotherapy.Here are some takeaways from her conversation with David Brühlmann:Green Revolution in Bioprocessing: Discover how microalgae can slash production costs by 70% and offer a sustainable alternative to traditional antibody manufacturing. Muriel explains how these photosynthetic organisms capture 7 tons of CO2 per kilogram of product - transforming antibody manufacturing both economically and environmentally.Rethinking Antibody Production: Learn why the conventional use of mammalian cells in antibody production is being challenged and how microalgae overcome the limitations of traditional methods, bringing life-saving drugs within reach for more people globally.Sustainable Impact: With a process that mirrors nature, Muriel's approach sets a new standard for eco-friendly biotech production. Find out how microalgae are changing not just the industry, but our world.We invite you to listen to this insightful conversation and explore how you can apply these groundbreaking ideas to your own work. Has Muriel's innovative approach inspired you? Share your thoughts or questions with us - we'd love to hear from you!If you are interested in antibody production, here is another episode worth listening:Episodes 47-48: Mastering Process Economics: Driving Down Costs in Antibody Production with Brian KelleyConnect with Muriel Bardor:LinkedIn: www.linkedin.com/in/muriel-bardor-47953024Email: muriel.bardor@univ-rouen.frAlga Biologics: www.algabiologics.comNext step:Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Featuring an interview with Dr Tiffany A Richards, including the following topics: Current treatment landscape for multiple myeloma (MM) (0:00) CAR (chimeric antigen receptor) T-cell therapy for the management of MM (10:22) Bispecific antibodies for relapsed/refractory MM (24:26) Case: A woman in her early 80s with relapsed MM receives teclistamab (35:56) Case: A man in his early 70s with multiregimen-refractory MM receives linvoseltamab on a clinical trial (44:06) Case: A woman in her early 60s with relapsed MM and extramedullary disease receives talquetamab (48:38) Role of nurses in transitions of care for patients with MM (53:15) Case: A man in his mid 70s with heavily pretreated MM experiences a response to teclistamab (58:56) Risk of second cancers with bispecific antibodies and other immunotherapy-based treatment approaches (1:00:55) NCPD information and select publications

Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.NCPD information and select publications here.

Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.NCPD information and select publications here.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHM865. CME credit will be available until March 9, 2026.Navigating MOGAD: Case-Based Insights Into Diagnosis, Treatment, and Management of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from UCB, Inc.Disclosure information is available at the beginning of the video presentation.

TWiV explains why RFK Jr.'s proposal to let H5N1 infections in birds ‘rip' is a bad idea, phase 1/2 trial of combined influenza/COVID mRNA vaccines, and how your first influenza virus exposure shapes the B cell response to influenza vaccination 50 years later. Hosts: Vincent Racaniello, Rich Condit, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2025 RFK Jr. says let H5N1 rip through flocks (NY Times) Combined flu/COVID mRNA vaccine (Nat Comm) Rare syndrome after COVID vaccination (NY Times, medRxiv) Imprinting lasts 50 years (Immunity) Imprinting protects against H5N1 and H7N9 (Science) Letters read on TWiV 1203 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Node-Focal Plane Image Competition Rich – Periodic cooking of eggs Vincent – The use of placebo controls in clinical trials Listener Picks Anne – Everything is Tuberculosis by John Green Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

I'm really excited to introduce today's guest, Dr. Pejman Katiraei!Mold exposure can have a profound impact on children's health, especially for kids with Autism Spectrum Disorder (ASD) and Pediatric Acute Neuropsychiatric Syndrome (PANS). In this episode, Dr. Pejman Katiraei shares his in-depth mold protocol designed specifically for children dealing with these complex conditions.

Featuring an interview with Ms Robin Klebig, including the following topics: Overview of the natural history and treatment landscapes of lymphoma subtypes (0:00) Structure and mechanisms of action of bispecific antibodies (23:41) Similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (28:14) Case: A man in his early 50s with multiagent/multiregimen-refractory follicular lymphoma who experienced disease progression with chimeric antigen receptor T-cell therapy now receives mosunetuzumab (39:14) Case: A woman in her mid 60s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives glofitamab (49:08) Case: A man in his mid 60s with R/R high-grade B-cell lymphoma with MYC and Bcl-2 rearrangements receives epcoritamab (52:57) Case: A man in his early 60s with composite lymphoma receives epcoritamab (56:55) NCPD information and select publications

Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.

Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.

About this episode: In the early days of the COVID-19 pandemic when there were no vaccines or treatments, convalescent plasma—antibody-containing blood from people who recovered from COVID—saved countless lives through Emergency Use Authorization. In this episode: special guest host Thomas Locke of MMI Monthly: From Bench To Breakthrough discusses the evolution of CCP therapy, from emergency use during the pandemic to now, nearly five years later, crossing the finish line with recent FDA approval as a potential treatment for immunocompromised patients. Guest: David Sullivan is a professor in Molecular Microbiology and Immunology and a researcher at the Johns Hopkins Malaria Research Institute. Host: Thomas Locke is the host of MMI Monthly: From Bench to Breakthrough and Malaria Minute,  podcasts from the department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Bloomberg School Researchers Support First Blood Center to Receive Full FDA Approval to Provide Convalescent Plasma for Patients Who Are Immunocompromised—Johns Hopkins Bloomberg School of Public Health Convalescent Plasma Offers ‘Blueprint' For Future Pandemics—The Hub How a Boy's Blood Stopped an Outbreak—The Wall Street Journal (Opinion) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.